Figure 6. Absence of TANs leads to increased infiltration and function of activated T cells.

A–E, Cxcr2^−/− and Cxcr2^+/+ mice were subcutaneously implanted with the 4662 cell line and sacrificed at 4 weeks (n = 8 per group). Graphs show mean ± s.d. of one experiment, which was done only once. *P < 0.05, ** P < 0.01, *** P < 0.001 (unpaired t-test). (A) Densities of tumor-infiltration CD4⁺ and CD8⁺ T cells. (B) Densities of CD44^hiCD62L⁺ memory, CD44^hiCD62L⁻ effector, and CD44^loCD62L⁺ or CD44^loCD62L⁻ naïve CD4⁺ or CD8⁺ T cells. (C) Densities of CD4⁺FOXP3⁺ Tregs CD11b⁺Ly6G⁺ tumor-associated neutrophils. (D) Ratios of the densities of CD4⁺CD44^hi or CD8⁺ effector T cells to the densities of CD4⁺FOXP3⁺ Tregs or CD11b⁺Ly6G⁺ TANs. (E) The percentage of CD44^hi activated or CD44^lo naïve CD4⁺ or CD8⁺ T cells that expresses IFNγ or IL17 after ex vivo stimulation with PMA/ionomycin for 5 hours at 37°C. (F) 4662 PDA tumor growth in Cxcr2^−/− and Cxcr2^+/+ mice treated with 200mg anti-CD4/anti-CD8 depleting antibodies or 200mg isotype every three days intraperitoneally (n ≥ 7 per group). Graph shows mean ± s.e.m. of one experiment. *** P ≤ 0.001 on Day 23 between isotype-treated Cxcr2^−/− and Cxcr2^+/+ mice (2-way ANOVA with column factor P value = 0.0277, Dunnett’s multiple comparison test). Results are representative of two independent experiments.